AFC-HD AMS Life Science Co., Ltd. Reports Consolidated Earnings Results for the Second Quarter Ended February 2021
April 05, 2021 at 03:10 am EDT
Share
AFC-HD AMS Life Science Co., Ltd. reported consolidated earnings results for the second quarter ended February 2021. For the quarter, the company reported net sales of JPY 9,150 million against JPY 7,892 million a year ago. Operating profit was JPY 1,016 million against JPY 565 million a year ago. Ordinary profit was JPY 1,026 million against JPY 567 million a year ago. Profit attributable to owners of parent was JPY 734 million against JPY 352 million a year ago. Basic earnings per share was JPY 52.83 against JPY 25.09 a year ago. Diluted earnings per share was JPY 52.70.
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
AFC-HD AMS LIFE SCIENCE CO., LTD. 
